Comparison of a picosecond alexandrite laser versus a Q-switched alexandrite laser for the treatment of nevus of Ota: A randomized, split-lesion, controlled trial
Comparison of a picosecond alexandrite laser versus a Q-switched alexandrite laser for the treatment of nevus of Ota: A randomized, split-lesion, controlled trial
复制标题
DOI：
10.1016/j.jaad.2019.03.016
复制
发表时间：
2020-08-01
影响因子：
13.8
通讯作者：
Lin, Tong
中科院分区：
文献类型：
--
作者：
Ge, Yiping;Yang, Ying;Lin, Tong
背景：新型皮秒激光器已可用于各种色素性疾病。目的：比较皮秒紫翠宝石激光（PSAL）和Q开关紫翠宝石激光（QSAL）治疗太田痣的疗效和安全性。方法：将56名入组受试者的每个病变分为2部分，并随机分配到PSAL或QSAL治疗组。每隔12周。疗效和安全性进行了测定，使用盲视觉评价和自我报告，在每个后续vision.Results：PSAL手臂实现了更好的清除率（5点量表，PSAL 4.53与QSAL 4.0），更少的会议（PSAL 5.26与QSAL 5.87）和更少的严重疼痛（视觉模拟量表，PSAL 5.61与QSAL 6.40）。患者对PSAL的满意度高于QSAL（Likert量表，4.5 vs 4.0）。炎症后色素沉着过度（PSAL 26%vs QSAL 34%）和色素减退（PSAL 21%vs QSAL 47%）的发生率也较低，PSAL比QSAL arm.Limitations：缺乏客观的评估和结果measures.Conclusion：PSAL表现出更好的临床效果和更少的不良事件比QSAL治疗太田痣。
Background: Novel picosecond lasers have been available for various pigmentary disorders. However, there are limited data directly comparing picosecond lasers and Q-switched lasers for treatment of nevus of Ota.Objective: To compare the efficacy and safety of a picosecond alexandrite laser (PSAL) with a Q-switched alexandrite laser (QSAL) for the treatment of nevus of Ota.Methods: Each lesion of 56 enrolled participants was split into 2 parts and randomly assigned to either the PSAL or QSAL treatment arm. Each lesion was treated in up to 6 sessions in 12-week intervals. Efficacy and safety were determined using blinded visual evaluation and self-report at each follow-up visit.Results: The PSAL arm achieved a significantly better clearance (5-point scale, PSAL 4.53 vs QSAL 4.0) with fewer sessions (PSAL 5.26 vs QSAL 5.87) and less severe pain (Visual Analog Scale, PSAL 5.61 vs QSAL 6.40). Patients were more satisfied with PSAL than QSAL (Likert scale, 4.5 vs 4.0). Occurrences of postinflammatory hyperpigmentation (PSAL 26% vs QSAL 34%) and hypopigmentation (PSAL 21% vs QSAL 47%) were also lower in PSAL than QSAL arm. Limitations: Lack of objective assessments and outcome measures.Conclusion: PSAL demonstrated better clinical results and fewer adverse events than QSAL for the treatment of nevus of Ota.